eyeforpharma Barcelona day one Day one: Tuesday 12 March Highlights include: Brent Saunders, CEO of Allergan, discusses the biggest challenges for the Share X eyeforpharma Barcelona day one https://pharmaphorum.com/event-coverage/eyeforpharma-barcelona-2019-day-1/
Curious2018: A thirst for innovation All too often pharma companies are accused of putting shareholders before their patients and society as a whole. Share X Curious2018: A thirst for innovation https://pharmaphorum.com/views-and-analysis/curious2018-innovation-thirst/
Oncolytics: the dawn of a new era in cancer treatment Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major Share X Oncolytics: the dawn of a new era in cancer treatment https://pharmaphorum.com/views-analysis-oncology/oncolytics-new-era-cancer-treatment/
Exclusive Live coverage: Curious2018 Future Insight: Day 3 Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share X Exclusive Live coverage: Curious2018 Future Insight: Day 3 https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-3/
Exclusive Live coverage: Curious2018 Future Insight: Day 2 Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share X Exclusive Live coverage: Curious2018 Future Insight: Day 2 https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-two/
Exclusive Live coverage: Curious2018 – Future Insight: Day One Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share X Exclusive Live coverage: Curious2018 – Future Insight: Day One https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-one/
Raising the bar in liver cancer therapy pharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a Share X Raising the bar in liver cancer therapy https://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success Gary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share X Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success https://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share X ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo https://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow Share X ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O https://pharmaphorum.com/event-coverage/asco-2018-bms-merck-co-locks-out-lung-cancer-i-o/
ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Share X ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more https://pharmaphorum.com/views-analysis-oncology/asco_2018-opdivo-nektar-abbvies-leukaemia/
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance Share X ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer https://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/